Last reviewed · How we verify
PEPIDH1M vaccine
At a glance
| Generic name | PEPIDH1M vaccine |
|---|---|
| Sponsor | Katy Peters, MD, PhD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (PHASE1)
- IDH1 Peptide Vaccine for Recurrent Grade II Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEPIDH1M vaccine CI brief — competitive landscape report
- PEPIDH1M vaccine updates RSS · CI watch RSS
- Katy Peters, MD, PhD portfolio CI